BJA Advance Access originally published online on April 4, 2006
British Journal of Anaesthesia 2006 96(6):678-685; doi:10.1093/bja/ael078
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acute toxic effects of Ecstasy (MDMA) and related compounds: overview of pathophysiology and clinical management
1 Department of Anaesthesia and Intensive Care Medicine, University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary Leicester LE1 5WW, UK
2 Academic Department of Accident and Emergency Medicine, Imperial College London 1st Floor QEQM Wing, St Mary's Campus, Norfolk Place, Paddington, London W2 1PG, UK
*Corresponding author. E-mail: andrew.p.hall{at}uhl-tr.nhs.uk
Since the late 1980s Ecstasy (3,4-methylenedioxymethamphetamine, MDMA) has become established as a popular recreational drug in western Europe. The UK National Criminal Intelligence Service estimates that 0.52 million tablets are consumed weekly in Britain. It has been reported that 4.5% of young adults (1534 yr) in the UK have used MDMA in the previous 12 months. Clinically important toxic effects have been reported, including fatalities. While the phenomenon of hyperpyrexia and multi-organ failure is now relatively well known, other serious effects have become apparent more recently. Patients with acute MDMA toxicity may present to doctors working in Anaesthesia, Intensive Care and Emergency Medicine. A broad knowledge of these pathologies and their treatment is necessary for anyone working in an acute medical speciality. An overview of MDMA pharmacology and acute toxicity will be given followed by a plan for clinical management.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Selvaraj, R. Hoshi, Z. Bhagwagar, N. V. Murthy, R. Hinz, P. Cowen, H. V. Curran, and P. Grasby Brain serotonin transporter binding in former users of MDMA ('ecstasy') The British Journal of Psychiatry, April 1, 2009; 194(4): 355 - 359. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Campbell and M. H. Rosner The Agony of Ecstasy: MDMA (3,4-Methylenedioxymethamphetamine) and the Kidney Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1852 - 1860. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Moon and J. Cros Role of dantrolene in the management of the acute toxic effects of Ecstasy (MDMA) Br. J. Anaesth., July 1, 2007; 99(1): 146 - 146. [Full Text] [PDF] |
||||
![]() |
M. R. Duffy and C. Ferguson Role of dantrolene in treatment of heat stroke associated with Ecstasy ingestion Br. J. Anaesth., January 1, 2007; 98(1): 148 - 149. [Full Text] [PDF] |
||||
E-letters:
Read all E-letters
- 'Ecstasy' (MDMA) and malignant hyperthermia
- Mark U. Gerbershagen, et al.
- British Journal of Anaesthesia, 15 Nov 2006 [Full text]
- 'Ecstasy' and MH
- Andrew P Hall, et al.
- British Journal of Anaesthesia, 27 Nov 2006 [Full text]


